Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Samsung Medical Center
Second Affiliated Hospital of Nanchang University
Sichuan University
Fondazione Ricerca Traslazionale
Sun Yat-sen University
Sun Yat-sen University
Zhejiang Cancer Hospital
The First Affiliated Hospital with Nanjing Medical University
Sun Yat-sen University
Peking University Cancer Hospital & Institute
Sun Yat-sen University
Shanghai Chest Hospital
Tianjin Medical University Cancer Institute and Hospital
Sichuan University
Tianjin Medical University Cancer Institute and Hospital
Peking University Cancer Hospital & Institute
Sun Yat-sen University
Xuanwu Hospital, Beijing
Tang-Du Hospital
The Affiliated Hospital of Qingdao University
Fudan University
Beijing Tsinghua Chang Gung Hospital
BGI, China
Sun Yat-sen University
Shanghai Chest Hospital
Shanghai Zhongshan Hospital
West China Hospital